INTRODUCTION
Achieving good glycemic control in efforts to prevent disease complications is the primary goal in the treatment of type 1 and type 2 diabetes [1] . Diabetes care guidelines and product labeling for current basal insulin analogs recommend regular blood glucose self-measurement [1] [2] [3] [4] [5] [6] to help people with diabetes maintain appropriate glycemic control and become more actively involved in their healthcare [7] [8] [9] . Insulin dose is also typically determined and titrated up or down as needed according to algorithms based on blood glucose results [1] . However, challenges exist that can prevent the achievement of glycemic targets with insulin, including perceptions on the part of patients and healthcare providers (HCPs) that insulin therapy can be burdensome or too complex to manage [10, 11] . Patients who take an active role in the management of their diabetes and titration of their insulin may feel more empowered to take charge of their self-care and have a stronger belief that their actions can influence their disease, thus leading to better treatment outcomes [12] [13] [14] . In determining how self-care can best be facilitated for patients with diabetes, the cost and burden of frequent glucose testing must be considered when designing treatment plans, as these can be significant factors when added to the health, quality of life (QoL), and financial toll of poorly controlled diabetes.
Numerous studies investigating the cost of self-measured blood glucose (SMBG) testing have found that it comprises a substantial portion of diabetes-related expenditures [15] [16] [17] [18] . In a retrospective database analysis in the US that included more than 45,000 patients, testing accounted for 27% of diabetes care costs: total combined blood glucose testing and insulin-related costs were $2,850 USD/patient/ year, with $772 USD/patient/year attributed to blood glucose testing alone [18] . In other countries, testing comprises an even higher percentage of diabetes care costs (e.g., 40% in Canada [16, 17] and 42% in Germany [15] ).
Insulin degludec (IDeg) is a new basal insulin (currently approved in Europe, Japan, Mexico and several other countries) with a flat, ultra-long action profile that may enable subjects to achieve glycosylated hemoglobin (HbA 1c ) levels closer to glycemic target with fewer hypoglycemic episodes [19] [20] [21] . It was thus hypothesized that IDeg could be titrated once-weekly based on a single pre-breakfast SMBG value, offering a simple, patient-focused titration algorithm that would encourage self-titration, enhancing patient empowerment as well as substantially reducing treatment costs by reducing the frequency of blood glucose measurements required for dose adjustments. In this study, after 26 weeks of treatment, the authors compared the efficacy and safety of two different self-titration algorithms for IDeg administered once-daily (OD) plus metformin, in insulin-naïve subjects with type 2 diabetes: a ''Simple'' algorithm, in which 4 unit (U) dose adjustments were made based on a single pre-breakfast SMBG measurement was compared with a ''Step-wise'' algorithm, in which dose adjustments were made in increments of 2 U (Table 1 ) based on the lowest of three consecutive pre-breakfast SMBG readings. In both groups, IDeg was adjusted once-weekly. The objective of this trial was to provide additional guidance on the use of IDeg in clinical practice by investigating whether good glycemic control could be attained with a more simplified titration schedule, involving fewer SMBG tests, than that previously employed during the IDeg Phase 3a development program.
METHODS
The study was conducted according to the Declaration of Helsinki, as revised in 2000 and 2008 [22] and ICH Good Clinical Practice (1996) guidelines [23] inclusion/exclusion criteria (randomized in error), non-compliance, or at the discretion of the investigator due to a safety concern. Subjects who were withdrawn after randomization were not to be replaced.
Study Design and Treatment
This was a multinational (conducted in the US, Spain, Finland, and Germany), Phase 3b, multi-center, two-armed, parallel group, Insulin degludec was administered OD at a starting dose of 10 U in both groups. Variation of injection time from day to day was permitted, as long as subjects maintained a minimum of 8 and a maximum of 40 h between injections. Self-adjustment of IDeg dose was to be performed once-weekly in both groups according to the algorithms outlined in Adverse events (AEs) and hypoglycemic episodes were documented throughout the study, with confirmed hypoglycemia defined as episodes of severe hypoglycemia (requiring assistance from another person) and episodes with PG value \3.1 mmol/L (56 mg/dL). Confirmed nocturnal hypoglycemic episodes were those occurring between 0001 and 0559 hours (inclusive). Laboratory safety variables, insulin dose, and body weight were recorded at pre-specified intervals. Two patient-reported outcome (PRO) questionnaires (Device-Specific questionnaires I and II) were self-completed at Visits 14 and 28 to assess subject satisfaction with the FlexTouch pen as an additional trial endpoint. The PRO questionnaire utilized here to assess patient satisfaction with FlexTouch had previously been used in other trials to assess satisfaction with the FlexPen Ò device (Novo Nordisk A/S, Bagsvaerd, Denmark) [24, 25] .
Statistical Methods
With 218 subjects, there was 85% power to demonstrate non-inferiority at 0.4% in evaluation of the per-protocol (PP) analysis set (defined as all subjects without major protocol violations who were exposed to treatment for [12 weeks and who had a valid assessment necessary for deriving the primary endpoint), accounting for an anticipated total of 15% that would not be included in the PP analysis set. Sample size was determined using a t-statistic under the assumption of a one-sided test of size 2.5% and a zero mean treatment difference. Data were reported using a 95% CI and P values for one-sided testing for non-inferiority at alpha = 0.025 for the primary analysis, and two-sided testing with alpha = 0.050 for all other analyses. Statistical analyses of all efficacy and patient-reported outcome endpoints were based on the full analysis set (FAS), defined as all randomized subjects, and followed the intention-to-treat Change from baseline in HbA 1c after 26 weeks was analyzed using an analysis of variance (ANOVA) method with treatment, region, sex, and antidiabetic therapy at screening as fixed factors, and age and baseline antidiabetic treatment at screening as fixed factors and age as covariate.
RESULTS
Participants were allocated 1:1 to the IDeg Simple (n = 111) and IDeg
Step-wise (n = 111) arms ( 
Subjects in the IDeg
Step-wise arm had a slightly longer mean duration of diabetes. The majority of participants in both groups were taking two OADs at baseline (61/111 subjects, 55%); *21%
in each group were taking [2 OADs, and *24%
in each group were taking 1 OAD. The most Step-wise subjects were withdrawn due to AEs; five IDeg Simple and seven IDeg Step-wise subjects were withdrawn due to meeting withdrawal criteria; and three subjects in each group were withdrawn due to reasons classified as ''other'' (Fig. 1) .
HbA 1c decreased from baseline to week 26 in both groups; -1.09% with IDeg Simple , to 7.0%, and -0.93% with IDeg
Step-wise , to 7.2% (Fig. 2a) (Fig. 3b) , with no significant difference between groups (P = 0.2047).
The observed daily insulin dose after 26 weeks was 62 U (0.61 U/kg) in the IDeg Simple arm and 48 U (0.50 U/kg) in the IDeg Step-wise arm. Up to week 4, mean doses were similar, after which the mean dose in the Simple arm was higher. The increase in IDeg dose per week began to level off in the IDeg Step-wise arm at week 14. Although subjects were permitted to adjust their dose by increments larger than 4 U in the IDeg Step-wise arm, the mean weekly incremental increase was B3 U. No safety concerns were raised during this trial. Please see Table 3 occurred, all of which were considered by the investigator to be unlikely related to treatment.
No IDeg-related medication errors were reported. In the Device-Specific questionnaires, designed to assess satisfaction with the insulin delivery device, more than 90% of subjects at week 12 and week 26 indicated the highest levels of satisfaction (response category 1 or 2) with FlexTouch in categories such as confidence in using the pen, ease in learning to use the device, ease in holding the pen stable or seeing arthralgia and blurred vision (1 subject); toxicity to various agents (1 subject); astrocytoma (1 subject); acute myocardial infarction (1 subject). IDeg
Step-wise : liver metastases (1 subject); intervertebral disc protrusion (1 subject); worsening of type 2 diabetes/vitamin D deficiency/anterior pituitary disorder/depression (1 subject). IDeg Simple : withdrawal of consent (2 subjects), investigator decision to withdraw subject due to safety or non-compliance (2 subjects), randomized in error (1 subject). IDeg
Step-wise : withdrawal of consent (2 subjects), investigator decision to withdraw subject due to safety or non-compliance (1 subject), randomized in error (4 subjects). à IDeg Simple : lost to follow-up (2 subjects) and withdrawn after 11.7 weeks of treatment due to HbA 1c increased (1 subject) IDeg Step-wise : lost to follow-up (3 subjects). AE adverse event, FAS full analysis set, IDeg insulin degludec, SAS safety analysis set Please refer to Table 4 for additional details on the results of the questionnaires (Table 4 contains a subset of the total questions surveyed in this trial). Treatment-emergent events occurring after first exposure and no later than 7 days after last exposure. Safety analysis set. n number of patients with events, % proportion of patients with events, E number of events, R number of events per 100 patient-years
DISCUSSION
IDeg and insulin glargine as demonstrated by non-inferiority in terms of change in HbA 1c ,
were 26 or 52 weeks in duration, enrolled insulin-naïve subjects (except for the BEGIN Basal-Bolus T2 study in which insulin aspart Step-wise arms. As shown in Fig. 3a [30] and with insulin glargine [31] [32] [33] , in which subjects experienced reductions in HbA 1c with a good safety profile when self-adjusting doses using trial-specified algorithms. In addition, patient acceptance of the insulin delivery device used to administer doses is a factor that appears to influence adherence and persistence with a given treatment regimen [34] [35] [36] [37] . It has been reported that positive perceptions of convenience also play an important role in the persistence of pen use [38] . In this trial, although it was not designed to compare methods of insulin administration, high levels of satisfaction with the FlexTouch insulin pen device were reported in both treatment arms and all subjects indicated that they would recommend the pen to others. This reflects the experiences of patients in other IDeg trials using the same device, in which the majority of patients reported ease in using the pen and a high degree of satisfaction with FlexTouch [39] [40] [41] [42] [43] . In this study, insulin degludec was used in both arms of the trial. The effectiveness and safety of the two titration algorithms used with insulin degludec may not apply to treatment and decision-making with other basal insulins. This could represent a limitation of the study. 
CONCLUSION
Achieving good glycemic control in patients with type 2 diabetes is an important way to prevent or limit diabetes complications, and control the costs of intensified healthcare utilization stemming from these complications. SMBG is an integral part of effective diabetes management; however, glucose meters, test strips, lancets, and alcohol wipes are consumable items that comprise on-going expenses, with test strips identified as a major driver of these costs [15] [16] [17] [18] . New medications and treatment regimens that permit a reduction in the number of SMBG measurements without compromising clinical outcomes would likely benefit all basal insulin-treated patients who may find current algorithms confusing or cumbersome. These patients may be more likely to adhere to a simpler regimen that ultimately results in improved health outcomes and lower healthcare costs. This trial demonstrates that IDeg, titrated using either the Simple or Step-wise algorithm, leads to good glycemic control and is well tolerated, offering individualized titration regimens that best meet patient needs.
ACKNOWLEDGMENTS
The study and article publication charge were sponsored by Novo Nordisk A/S (Bagsvaerd, Denmark 
